Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 5/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 5/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289600 | 0.90 | GRIA4 (0.45) | GRIA2GRIA4 | |
| SCHEMBL8289552 | 0.89 | GRIA4 (0.46) | GRIA2GRIA4PGR | |
| SCHEMBL8289608 | 0.88 | GRIA2 (0.45) | GRIA2GRIA4AKR1C3FFAR1FFAR4 | |
| SCHEMBL4562563 | 0.87 | HRH2 (0.42) | GRIA2GRIA4BACE1 | |
| SCHEMBL8288508 | 0.85 | KDM4E (0.47) | GRIA2GRIA4FFAR1 | |
| SCHEMBL8289606 | 0.83 | GRIA4 (0.47) | GRIA2GRIA4 | |
| SCHEMBL8289610 | 0.82 | GRIA4 (0.40) | GRIA2GRIA4FFAR4 | |
| SCHEMBL8289845 | 0.78 | GRIA4 (0.57) | GRIA2GRIA4 | |
| SCHEMBL8288506 | 0.77 | GRIA4 (0.76) | GRIA2GRIA4 | |
| SCHEMBL8289438 | 0.77 | FFAR1 (0.54) | GRIA2GRIA4XDHFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | GRIA2 17/4885GRIA4 16/4885BACE1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.